SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IMDX

Insight Molecular Diagnostics Inc. (IMDX)

NASDAQ: IMDX · Real-Time Price · USD
Healthcare · Diagnostics & Research
$1.66+$0.07 (+4.40%)
 
Market cap
$54.4M
Insider Score
Analyst consensus
Market Cap$54.38M-73.5%
Revenue (ttm)$1.97M
Net Income-$42.08M
EPS-$1.27
Shares Out32.76M
PE Ration/a
Forward PE-2.48
Dividendn/a
Ex-Dividend Daten/a
Volume168,406
Open$1.64
Previous Close$1.59
Day's Range$1.59 - $1.80
52-Week Range$1.50 - $7.51
Betan/a
AnalystsBuy
Price Target$7.25(+336.75%)
Earnings DateNov 16, 2026
+4.40% (1D)
No price history available.

About IMDX

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Address
2 International Plaza Dr., Nashville, TN, 37217, United States
Market Cap
54 million
Employees
55
Industrial Classification
Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$6.00M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-10.67%
5 Days
-33.47%
1 Month
-47.52%
6 Months
-74.31%
1 Year
-73.50%

$IMDX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IMDX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IMDX's directors and management

Net Shares Purchased by Insiders−4M−2M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IMDX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

IMDX Revenue by Segment

Reading latest SEC filing…

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New IMDX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IMDX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from IMDX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
85
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$6.00M
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.